Skip to main content

Table 1 Baseline (2000) characteristics of the patients in EMECAR

From: Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort

Characteristic All studied patients Ever used aTNF or LEF Never used aTNF or LEF
n 789 210 (27%) 579 (73%)
Women 568 (72) 159 (76)* 409 (71)
Age (years) 61 ± 13 57 ± 12*** 63 ± 13
Age at rheumatoid arthritis onset (years) 48 ± 15 44 ± 13*** 50 ± 15
Rheumatoid factor-positive 592 (75) 167 (79)** 346 (70)
Any comorbidity 606 (77) 154 (73) 380 (77)
Any extra-articular rheumatoid arthritis 355 (45) 122 (58)* 226 (46)
Health Assessment Questionnaire score 1.2 ± 0.9 1.3 ± 0.8 1.2 ± 0.9
Disease activity score from 28-joint count with three parameters 4.1 ± 1.4 4.6 ± 1.4*** 3.9 ± 1.3
Larsen score 54 ± 27 57 ± 24 53 ± 27
  1. Data presented as n (%) or as mean ± standard deviation. Characteristics of those patients who used TNF antagonists (aTNF) or leflunomide (LEF) at any time of follow-up were compared with those of patients who did not. ***P < 0.001, **P < 0.01, *P < 0.05.